Company intelligence / Profile preview

Tetratherix

Sydney, New South Wales, Australiatetratherix.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Tetratherix has developed an injectable medical device based on a proprietary fluid matrix that accelerates natural regeneration of cartilage, bone, and interface tissues. The technology has demonstrated biosafety and efficacy in preclinical models. The company operates a GMP-compliant cleanroom facility for production.[2][3]

No published results from human clinical trials were found.

The company has received over $2.5 million in public grants/private investment.[3]

Therapeutic areas: OtherRheumatology
Modalities: Injectable biomaterialstissue scaffolds
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Tetramatrix

Phase 1

Indications: Prostate cancer, Dermal scarring, Bone reconstruction

Beyond the preview

Go deeper on Tetratherix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetratherix.

Explore the full profile